When Dr. Stanley Fineman started as an allergist in Atlanta, he told patients they should start taking their medications and prepare for the drippy, sneezy onslaught of pollen season around St. Patrick’s Day. That was about 40 years ago. Now he tells them to start around St. Valentine’s Day. Across
Digital check-ins, connected inhalers help control asthma
Daily check-ins help asthma patients track medication adherence and improve inhaler technique. (EMOCHA HEALTH)
A core challenge for asthma management is teaching patients how to properly use an inhaler. Asthma patients, many of them children, could avoid emergency department visits or using a rescue inhaler, if only they followed proper inhaler technique.
To take on that problem, LifeBridge Health in early 2020 enrolled 24 children at a Baltimore primary-care clinic in a two-month pilot program that uses asynchronous telehealth.
It’s an example of the growing arsenal of digital health tools physicians are using to tackle medication adherence a particular challenge for asthma patients.
717.5
-3.8%
(1) Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2) Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3) Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs.
Johnson & Johnson has announced its application with the FDA to obtain an EUA for its COVID-19 vaccine.
While this would help get the population vaccinated more quickly, there’s concern the company’s vaccine is not as effective as the Pfizer and Moderna vaccines.
Experts say there may not be a choice over which vaccine to choose until vaccine production can match population needs.
However, more effective vaccines will become available at a later time.
Experts emphasize that all three vaccines are safe and will help control the pandemic.
All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our coronavirus hub and follow our live updates page for the most recent information on the COVID-19 pandemic.